RedHill Biopharma Terminates License Agreement For Aemcolo, A Treatment For Traveler's Diarrhea, Will Be Officially Terminated On October 8, 2024

7/9/24 8:12:32 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $RDHL alert in real time by email

RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the mutual decision with Cosmo Technologies Ltd. ("Cosmo") to voluntary terminate their exclusive U.S. license agreement for Aemcolo, a treatment for traveler's diarrhea (the "License Agreement"). The License Agreement, initially dated October 17, 2019, will be officially terminated on October 8, 2024.

Get the next $RDHL alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RDHL

Date	Price Target	Rating	Analyst
9/15/2021	$23.00 → $21.00	Buy	HC Wainwright & Co.
8/31/2021	$22.00	Overweight	Cantor Fitzgerald

More analyst ratings

$RDHL
Market Insights

Live Market Insights

Redhill Biopharma Terminates Agreement With Movantik Acquisition, Valinor Pharma, And Hcr Redhill, And Received ~$9.9M In Cash And Gained Full Control Over An Additional $0.74M Currently Held In Restricted Account
In addition, the Agreement ends all existing credit ties with the Agreement parties, removes the existing lien against Talicia® and restores control over cash collections back to RedHill.
7/22/24 7:14:53 AM ET
$RDHL
Biotechnology: Pharmaceutical Preparations
Health Care
RedHill Biopharma Terminates License Agreement For Aemcolo, A Treatment For Traveler's Diarrhea, Will Be Officially Terminated On October 8, 2024
RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the mutual decision with Cosmo Technologies Ltd. ("Cosmo") to voluntary terminate their exclusive U.S. license agreement for Aemcolo, a treatment for traveler's diarrhea (the "License Agreement"). The License Agreement, initially dated October 17, 2019, will be officially terminated on October 8, 2024.
7/9/24 8:12:32 AM ET
$RDHL
Biotechnology: Pharmaceutical Preparations
Health Care
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Nexalin Technology (NASDAQ:NXL) shares rose 55.8% to $1.62 during Tuesday's after-market session. The market value of their outstanding shares is at $12.0 million. Dynatronics (NASDAQ:DYNT) stock rose 14.74% to $0.4. The company's market cap stands at $2.1 million. Oncology Institute (NASDAQ:TOI) shares moved upwards by 10.8% to $0.45. The market value of their outstanding shares is at $33.5 million. SAB Biotherapeutics (NASDAQ:SABS) stock rose 8.94% to $2.8. The market value of their outstanding shares is at $25.8 million. Bone Biologics (NASDAQ:BBLG) shares moved upwards by 8.04% to $1.61. The company's market cap stands at $1.7 million. Virpax Pharmaceuticals (NASDAQ:VRPX) s
6/18/24 4:31:14 PM ET
$BBLG
$BIOL
$DYNT
$ENSC
Industrial Specialties
Health Care
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations

$RDHL
Press Releases

Fastest customizable press release news feed in the world

Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors
- Dr. Almenoff brings more than 25 years of drug development and leadership experience to the Actinium Board of Directors - Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the appointment of June Almenoff, M.D., Ph.D. to its Board of Directors. Dr. Almenoff is an accomplished biopharma executive with over 25 years of senior leadership and drug development experience. She currently serves as a Board Director and advisor to nu
11/4/24 7:30:00 AM ET
$ATNM
$AVTX
$RDHL
$TENX
Biotechnology: Pharmaceutical Preparations
Health Care
RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND
RedHill has been selected to provide a presentation to further elaborate on opaganib's potential to U.S. government representatives at the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense's (JPEO-CBRND) "Host Directed Therapeutics Industry Day" -- Based on reviews, feedback, and discussion, the judges selected for presentation those therapeutics that demonstrated capability in the prophylaxis, post-exposure prophylaxis, and the treatment of exposure to viruses, bacteria and toxins. The meeting is scheduled to take place October 29-30, 2024, at the United States Patent and Trademark Office in Alexandria, VA -- The JPEO-CBRND manages U.S. government inv
10/28/24 7:00:00 AM ET
$RDHL
Biotechnology: Pharmaceutical Preparations
Health Care
RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury
The collaboration outlines plans for multiple in vivo studies, designed to test opaganib as a potential medical countermeasure to treat phosgene inhalation injury. The collaboration aims to determine whether opaganib can advance into further definitive U.S. government-sponsored development under the FDA's Animal Rule pathway to approval Used as a chemical weapon during World War I, phosgene, a toxic, colorless chemical, is today widely used in industrial processes for the manufacture of plastics and pesticides. The U.S. Environmental Protection Agency (EPA) identified 123 sites in the United States that could potentially expose millions of people to phosgene due to plant malfunction or biote
10/22/24 7:00:00 AM ET
$RDHL
Biotechnology: Pharmaceutical Preparations
Health Care

RedHill Biopharma Announces Q1/22 Highlights: On Track for Positive Cash from Operations in H2/22
Targeting positive cash from operations to start during H2/22[1] Focus on earlier achievement of operational profitability thanks to a recently implemented comprehensive cost reduction plan, with expected operational cost savings of approximately $50 million over the next 18 months Continuous implementation of disciplined cost controls reduced Q1/22 cash used in operating activities by more than 70% to approximately $4 million, compared to approximately $15 million in Q4/21 Net revenues of $18.2 million in Q1/22; Cash balance[2] of $45 million as of March 31, 2022 Talicia® TRx up 12.8% over Q4/21 and Movantik® continues strong Q4/21 prescription performance Amendment improves key covenants i
6/23/22 7:00:00 AM ET
$RDHL
Biotechnology: Pharmaceutical Preparations
Health Care
RedHill Biopharma to Host First Quarter 2022 Financial Results and Operational Highlights Webcast on June 23, 2022
TEL AVIV, Israel and RALEIGH, N.C., June 17, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its first quarter 2022 financial results and operational highlights on Thursday, June 23, 2022. The Company will host a conference call and webcast on Thursday, June 23, 2022, at 8:30 a.m. EDT, during which it will present key highlights for the first quarter of 2022. The webcast including slides will be broadcast live on the Company's website, https://ir.redhillbio.com/ev
6/17/22 8:30:00 AM ET
$RDHL
Biotechnology: Pharmaceutical Preparations
Health Care
RedHill Biopharma Reports Operational Highlights and Fourth Quarter & Full Year 2021 Financial Results
TEL AVIV, Israel and RALEIGH, N.C., March 17, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its operational highlights and financial results for the fourth quarter and full year ended December 31, 2021. Dror Ben-Asher, RedHill's Chief Executive Officer, said: "In 2021, RedHill's team delivered record revenues against a pandemic backdrop, overall contribution of commercial operations to the company was positive for the first time in Q4/21 and positive late-stage clinical data for two novel oral COVID-19 drugs. A very strong fourth quarter for both Talicia® and Movantik®, coupled with disciplined c
3/17/22 7:59:00 AM ET
$RDHL
Biotechnology: Pharmaceutical Preparations
Health Care

RedHill Biopharma Terminates License Agreement For Aemcolo, A Treatment For Traveler's Diarrhea, Will Be Officially Terminated On October 8, 2024

Chat with this insight

Recent Analyst Ratings for
$RDHL

$RDHL
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

HC Wainwright & Co. reiterated coverage on Redhill Biopharma with a new price target

Cantor Fitzgerald initiated coverage on Redhill Biopharma with a new price target

Redhill Biopharma downgraded by WBB Securities with a new price target

$RDHL
Leadership Updates

Live Leadership Updates

Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors

$RDHL
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Redhill Biopharma Ltd.

SEC Form SC 13G filed by Redhill Biopharma Ltd.

SEC Form SC 13G filed by Redhill Biopharma Ltd.

$RDHL
SEC Filings

SEC Form 6-K filed by Redhill Biopharma Ltd.

SEC Form 6-K filed by Redhill Biopharma Ltd.

SEC Form 6-K filed by Redhill Biopharma Ltd.

$RDHL
Market Insights

Live Market Insights

Redhill Biopharma Terminates Agreement With Movantik Acquisition, Valinor Pharma, And Hcr Redhill, And Received ~$9.9M In Cash And Gained Full Control Over An Additional $0.74M Currently Held In Restricted Account